Long-term results of golimumab therapy for rheumatoid arthritis. Therapy compliance issues
The goal of therapy for rheumatoid arthritis (RA) is to suppress inflammation, to prevent or delay destructive changes in the joints, and to normalize functions during the longest monitoring of the course of RA. The data of randomized controlled trials and national registries are of great importance...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2016-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/683 |
| _version_ | 1797876752988504064 |
|---|---|
| author | N. V. Chichasova |
| author_facet | N. V. Chichasova |
| author_sort | N. V. Chichasova |
| collection | DOAJ |
| description | The goal of therapy for rheumatoid arthritis (RA) is to suppress inflammation, to prevent or delay destructive changes in the joints, and to normalize functions during the longest monitoring of the course of RA. The data of randomized controlled trials and national registries are of great importance to a clinician. The paper reviews the literature data characterizing the long-term results of RA therapy with the tumor necrosis factor-α inhibitor golimumab (GLM) and patient compliance with the therapy. Treatment with GLM at the registered subcutaneous dose of 50 mg once every 4 weeks gives rise to an effect in the vast majority of patients regardless of the type of previous ineffective therapy, the dose of concurrently administered methotrexate, the number of previous ineffective disease-modifying antirheumatic drugs, and the use and nonuse of glucocorticoids. GLM is characterized by a long-term (as long as 5 years) effect with suppressed progression of destruction, functional recovery, and satisfactory tolerability with no additional risk for adverse events as the therapy is continued. |
| first_indexed | 2024-04-10T02:07:35Z |
| format | Article |
| id | doaj.art-7f35703331b247c1ab2dd33af675f5b0 |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:07:35Z |
| publishDate | 2016-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-7f35703331b247c1ab2dd33af675f5b02023-03-13T08:39:24ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2016-06-01102434910.14412/1996-7012-2016-2-43-491974Long-term results of golimumab therapy for rheumatoid arthritis. Therapy compliance issuesN. V. Chichasova0Кафедра ревматологии ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова», Москва, Россия 119991, Москва, ул. Трубецкая, 8, стр. 2The goal of therapy for rheumatoid arthritis (RA) is to suppress inflammation, to prevent or delay destructive changes in the joints, and to normalize functions during the longest monitoring of the course of RA. The data of randomized controlled trials and national registries are of great importance to a clinician. The paper reviews the literature data characterizing the long-term results of RA therapy with the tumor necrosis factor-α inhibitor golimumab (GLM) and patient compliance with the therapy. Treatment with GLM at the registered subcutaneous dose of 50 mg once every 4 weeks gives rise to an effect in the vast majority of patients regardless of the type of previous ineffective therapy, the dose of concurrently administered methotrexate, the number of previous ineffective disease-modifying antirheumatic drugs, and the use and nonuse of glucocorticoids. GLM is characterized by a long-term (as long as 5 years) effect with suppressed progression of destruction, functional recovery, and satisfactory tolerability with no additional risk for adverse events as the therapy is continued.https://mrj.ima-press.net/mrj/article/view/683ингибиторы фактора некроза опухоли αголимумабдлительная терапияэффективностьбезопасность |
| spellingShingle | N. V. Chichasova Long-term results of golimumab therapy for rheumatoid arthritis. Therapy compliance issues Современная ревматология ингибиторы фактора некроза опухоли α голимумаб длительная терапия эффективность безопасность |
| title | Long-term results of golimumab therapy for rheumatoid arthritis. Therapy compliance issues |
| title_full | Long-term results of golimumab therapy for rheumatoid arthritis. Therapy compliance issues |
| title_fullStr | Long-term results of golimumab therapy for rheumatoid arthritis. Therapy compliance issues |
| title_full_unstemmed | Long-term results of golimumab therapy for rheumatoid arthritis. Therapy compliance issues |
| title_short | Long-term results of golimumab therapy for rheumatoid arthritis. Therapy compliance issues |
| title_sort | long term results of golimumab therapy for rheumatoid arthritis therapy compliance issues |
| topic | ингибиторы фактора некроза опухоли α голимумаб длительная терапия эффективность безопасность |
| url | https://mrj.ima-press.net/mrj/article/view/683 |
| work_keys_str_mv | AT nvchichasova longtermresultsofgolimumabtherapyforrheumatoidarthritistherapycomplianceissues |